WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. Get in Touch. WuXi AppTec acquired Pharmapace in San Diego, California, to enhance biometrics services for clinical development . Wuxi Apptec, Inc. has 485 total employees across all of its locations and generates $221.51 million in sales (USD). B.S. WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. Company profile page for WuXi PharmaTech Cayman Inc including stock price, company news, press releases, executives, board members, and contact information Announcements. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Ph.D. in Organic Chemistry from Columbia University. [11] In 2016, WuXi's STA subsidiary opened a new campus in Changzhou[12] and operations in San Diego. Ph.D. in Organic Chemistry from Yale University. [13] In 2017, WuXi acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO). Joined WuXi AppTec in 2004 as Chief Scientific Officer. Corporation: Owner at Publication: China: No. WUXI APPTEC CO., LTD. contact information is shown below: Owner: WUXI APPTEC CO., LTD. Joined WuXi AppTec since August 2007, Mr. Hu has demonstrated his extraordinary leadership to expand WuXi's business globally. WuXi … [15][16] The subsidiary had offices in Boston and Woburn, Massachusetts (US); Reykjavik (Iceland) and Shanghai (China). As … Corporation: Original Applicant: China: No. Modern Commercial Production and Office Space. WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Company Number assigned to this business is 3150064 and state of formation is DE. Revendication : "George Soros owns the WuXi PHARMA LAB located in Wuhan, China where COVID-19 was developed and conveniently Broke Out." Ping An … Ph.D. in Physical Chemistry from Monash University in Australia. Corporation: Owner at Publication: China: Bridge 5, Binhu District, 214091 Wuxi: Wuxi Apptec Co.,ltd. WuXi AppTec has raised a total of $1.6B in funding over 6 rounds. Ph.D. in Organic Chemistry from Columbia University. About WuXi AppTec. Formerly Sr. Held progressive positions as Assistant President of Huawei University, Consumer Business Group (CBG) South Pacific Region President, HRVP of CBG, VP of Huawei Group HR department etc. Formerly a tech lead of the Cards team at Twitter in San Francisco. WuXi's founder is Dr. Ge Li, an organic chemist, who founded WuXi PharmaTech in Shanghai in December 2000. [16], Multinational public medicines and medical device company, WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, WuXi PharmaTech Announces First-Quarter 2013, Learn how and when to remove these template messages, Learn how and when to remove this template message, "WuXi PharmaTechListed Among Asia's Fastest Growing Companies, Third Year Running", WuXi Acquires Chinese Clinical CROs MedKey and Jiecheng, WuXi PharmaTech Acquires Abgent, a Leading Producer of Biological Research Reagents, Conyers advises New WuXi Life Science Ltd. in connection with US$3.3 billion buyout, WuXi AppTec's STA Subsidiary Opens New Campus In Changzhou, "DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris". Vice Chairman and Global Chief Investment Officer at WuXi AppTec. That year WuXi also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market. Senior Vice President, Global Head of Human Resources. EMBA from China Europe International Business School. Listed on the HKEX on December 13, 2018, the company's major shareholders are HKSCC Nominees Ltd, G&C VI Ltd and Summer Bloom Investments (I) PTE. At the same year, WuXi acquired MedKey, a China-based clinical research company,[6] and Abgent, a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery. Senior Vice President, Head of Government Affairs and Policy Research. WuXi AppTec Expands Site in the United States for Drug Development Testing Services SHANGHAI and CRANBURY, N.J., April 18, 2018 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey. WuXi AppTec is a leading R&D outsourcing company serving the pharmaceutical, biotechnology and medical device industries. Located in the Philadelphia Navy Yard, this 95,000 square-foot, 3-story commercial lab production and office facility is home to WuXi AppTec. [10], In 2015, WuXi completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited. Define WuXi AppTec Patent Rights. WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. Played important roles in R&D and commercialization of multiple innovative drugs for global launches. WuXi AppTec is funded by 5 investors. Ph.D. in Computer Science and Engineering from University of Michigan. WuXi AppTec, Inc. company type is Business Corporation. Ph.D. in Organic Chemistry from University of Notre Dame. Brand: P: Description: Pharmaceutical research and development; Scientific research and development; … We provide an open-access R&D capability and technology platform to … 1993 A team including Drs. Prior to joining WuXi AppTec, he was founder and CEO of VIDA Sciences, a company serving contract research organizations focusing on performance improvement. Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating … +. 2020. Lijun International Pharmaceutical (Holding) Co. Ltd. Shanghai Pharmaceuticals Holding Co., Ltd. Ping An Insurance (Group) Company of China, https://en.wikipedia.org/w/index.php?title=WuXi_AppTec&oldid=1021599492, Companies listed on the New York Stock Exchange, Pharmaceutical companies established in 2000, Short description is different from Wikidata, Articles with a promotional tone from August 2015, Articles lacking reliable references from July 2017, Articles with multiple maintenance issues, Articles with unsourced statements from March 2021, Creative Commons Attribution-ShareAlike License, Small Molecule Therapeutics R&D, Manufacturing and Testing, Biologicals Therapeutics R&D and Manufacturing, Gene- and Cell-based Therapies Manufacturing, This page was last edited on 5 May 2021, at 16:22. Home > Projects > WuXi AppTec. Investors | WuXi AppTec. +. WuXi opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi City in 2011. At the same year, WuXi acquired MedKey, a China-based clinical research company, and Abgent, a San Diego company and one of... in Electrical Engineering from Northwestern University and MBA from Columbia Business School. WuXi AppTec. (Bloomberg) — Separate Hong Kong initial public offerings (IPOs) by biotech firm WuXi AppTec and Fosun Tourism, owner of the Club Med resort chain, will raise a collective $1.5 billion in the latest of a yearlong string of offshore listings by Chinese companies, sources familiar with the deals said. By Building an Open-access Platform with the Most Comprehensive Capabilities and Technologies in the Global Healthcare Industry, Environmental, Social and Governance (ESG). Mr. Hu has an MBA and Master's degree in Chemistry from Carnegie Mellon University. Formerly worked at Zeneca, BSM, Lexicon. means all patents and patent applications of any kind throughout the world relating to WuXi AppTec Know-How or to the Process which from time to time WuXi AppTec is the owner of or is entitled to use WuXi AppTec developed from a laboratory of 7000 square feet to 29 sites worldwide. Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science ... See more ». He is a strong business leader with broad experiences in operations management, new business creation and development, venture investments, merger and acquisitions and financial management. Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox. Senior Vice President, Head of STA DP Business. Wuxi Apptec Co.,ltd. As a result of the merger, New WuXi Life Science Limited acquired the company in a cash transaction valued at approximately US$3.3 billion. Almost 20 years of experiences and expertise in business, operations and HR management in Huawei. Our History. A pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Coordinating Changes Inside and Out The Medicine Maker's 2019 Power List - one of the industry's most prominent 'Business Captains'. The global pharmaceutical and medical device open-access capability and technology platform | WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Over 27 years' experience in Organic Chemistry, small molecule API process R&D and Manufacturing, Process technology transfer as well as overall CMC. Our team has a proven track record developing customized programs that leverage our many years of industry-leading experience. in Chemistry from Peking University and Ph.D. in Organic Chemistry from University of Minnesota. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, and served as Vice President and Head of Asia R&D at Pfizer and as Executive Director and head of Pfizer's global R&D strategic management group. WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As a premier Contract Development and Manufacturing Organization (CDMO), … In the same year, WuXi acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. Formerly Vice President of International Discovery Service Unit, responsible for the management of Shanghai, Wuhan and Tianjin site. In the same year, WuXi acquired Crelux GmbH, a structure-based drug discovery provider based in Munich, Germany. [14], WuXi AppTec provides services to its customers primarily in the pharmaceutical, biotech, and other life science industries, as well as research institutes, disease-focused and non-profit foundations. [5], WuXi opened a large-scale manufacturing facility in Jinshan in 2010. Senior Vice President, Chief Financial Officer. One of the founding scientists of the company. Awards and honors include "2018 SAPA Distinguished Achievement Award", "2018 The 40 Most Influential People in Pharmaceutical Industry in Commemoration of the 40th Anniversary of Reform and Opening-up", "2016 CBA Brilliant Achievement Award", "2015 SCRIP Executive of the Year Award", "2015 The 25 Most Influential People in Biopharma", "2009 The 60 Most Influential People during 60 Years Pharmaceutical Development in China", "2008 Forbes 25 Notable Chinese-Americans", and "2007 Ernst & Young Entrepreneur of the Year China". Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco. Ph.D. in Organic Chemistry from University of Wisconsin-Milwaukee. One of our founders, entrepreneur, formerly Vice President of Domestic Marketing of WuXi AppTec. The founder is Ge Li. February 9, 2021 FinSMEs News. Financial Reports and Presentations. WuXi AppTec (WuXi pronounced Wu-shee) is a global pharmaceutical, biopharmaceutical, and medical device company. Senior Vice President, Chief Digital Officer. Prospectus. Ltd. Rivals that have direct and indirect competition with WuXi AppTec include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, … The first WuXi Healthcare Forum held in Shanghai. WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the … In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. WuXi opened a toxicology facility in Suzhou in 2009. 5 Bridge Mashan, Binhu District Wuxi 21400 : Wuxi Apptec Co., Ltd. He is a strong business leader with broad experiences in operations management, new business creation and development, venture investments, merger and acquisitions and financial management. Formerly Director of Technical Operations at Vertex. Wealth of experience in gene and cell therapy, and biopharmaceutical technical development, manufacturing operations, engineering and strategy. There are 5 areas of focus for services:[citation needed], In 2015, the company launched the subsidiary WuXi NextCODE following the acquisition of NextCODE Health, a bioinformatics startup company which emerged from the Icelandic firm deCODE genetics in 2013. WuXi AppTec Inc WuXi AppTec, Inc. operates as pharmaceuticals company. Master and bachelor degrees in legal major from Wuhan University. Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox. Dr. Chen has profound experience in leading strategic designs and practical applications in healthcare big data and Artificial Intelligence. serial# trademark filing date status date trademark owner watch; live : 90150864: logo: sep 01, 2020: jan 07, 2021: wuxi apptec (shanghai) co., ltd. Over 20 years' experience in drug delivery technologies, formulation, drug product process development and manufacturing, CMC regulatory submission. Stock Information. Over 20 years' experience in pharmaceutical development and manufacturing. He founded Tencent Medical Big Data Lab, and Alibaba Health's Big Data and AI team. +86 (512) 6603-7138. [3], WuXi established services in synthetic chemistry in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007. BIO KOREA 2020 Company Presentation_Please check the participating company. Executive Vice President, Chief Scientific Officer, Head of DDSU. [8] In 2013, WuXi formed a joint venture with the global clinical contract research organization PRA International (now called PRA Health Sciences) to build a clinical research business in China. Ph.D. in medicinal chemistry from Peking University. Wuxi Apptec Co., Ltd. Currently only standard biocompatibility, biologics, and osteoinduction testing at our St. Paul facility can be ordered through WOS per the following link: https://wos.wuxiapptec.com/ . Their latest funding was raised on Mar 6, 2016 from a Debt Financing round. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi City in 2011. The company covers the development cycle through five core operations, including small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics. 5 Bridge Mashan, Binhu District Wuxi 21400 : Case File Statements: CODE: DESCRIPTION: CC0000: Color Is Not Claimed As A Feature Of The Mark. OUR HISTORY. WuXi AppTec, founded in December, 2000 and headquartered in Wuxi, is Ge Li. Ph.D. in biochemical engineering from Massachusetts Institute of Technology. Owner Address: FREE TRADE ZONE 288 FU TE ZHONGLU, WAIGAOQIAO SHANGHAI 200131 China: Owner Web Site: Owner Phone: Owner Toll Free: Owner Fax . Vice Chairman, Global Chief Investment Officer. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the … Bill Harrison has over 30 years’ experience in the contract research organization industry with a strong record of growth. 1318 Wuzhong Avenue, Wuzhong District, Suzhou, 215104 China. Corporation: Owner At Registration: China: Bridge 5, Binhu District, 214091 Wuxi: Wuxi Apptec Co.,ltd. Joined WuXi AppTec since August 2007, Mr. Hu has demonstrated his extraordinary leadership to expand WuXi's business globally. WuXi AppTec announced listing of Initial Public Offering of Common Stock on the Shanghai Stock Exchange (stock code: 603259.SH) WuXi AppTec listed H shares on the Hong Kong Stock Exchange (stock code: 2359.HK) 2019. [9], In 2014, WuXi opened a new biologics biosafety testing facility in Suzhou. Senior Vice President, Head of STA API Business. Formerly Managing Director and senior M&A banker at Citigroup and Merrill Lynch, Mr. Chu led the execution on many of the most strategic and transformative cross-border deals. Over 27 years of experience in the biotech and drug discovery sector, most recently as Vice President of External Research Solutions at Pfizer. Held multiple management positions in the U.S., UK, Germany and China while at Pfizer and Bayer. added Dr. Minzhang Chen, CEO of WuXi STA.About WuXi STASTA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with operations in China and the United States. Find the latest Institutional Holdings data for Wuxi AppTec Co. Ltd. - Class H (WUXIF) at Nasdaq.com. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it … The Company provides testing and research discovery, development, toxicology, clinical, and bioanalytical services. Senior Vice President, Chief Operating Officer. Fellow of Process Chemistry at Schering-Plough/MSD. Penntex worked closely with owner Liberty Property Trust, tenant WuXi Apptec and project subcontractors to expedite evaluation and planning to accommodate the change – determining the most efficient, expedient and cost-effective options. Scientist and entrepreneur leading WuXi since its founding in 2000. B.S. Every drug can be made and every disease can be treated through building an open-access platform with the most comprehensive capabilities and technologies in the global healthcare industry. WuXi AppTec developed from a laboratory of 7000 square feet to 29 sites worldwide. Corporate Governance. WuXi AppTec, one of the largest CROs in China, has just acquired a Shanghai-based preclinical counterpart, HD Biosciences, building further on its core business. WuXi's founder is Dr. Ge Li,[2] an organic chemist, who founded WuXi PharmaTech in Shanghai in December 2000. Wuxi Apptec, Inc. is located in Saint Paul, MN, United States and is part of the Pharmaceutical Manufacturing Industry. WuXi AppTec(Suzhou) Drug Safty Evaluation (Toxicology, Pharmacology, DMPK), Oncology New Drug Research&Development, Medical Device Testing. Senior Vice President, U.S. Chief Operating Officer. He is a strong business leader with broad experiences in operations management, new business creation and development, venture investments, merger and acquisitions and financial management. Announcements. [4] The company opened chemistry facilities in Tianjin in 2007. Over 29 years' experience in medicinal chemistry, formerly Research Advisor at Eli Lilly, Vion Pharmaceuticals and Bristol-Myers Squibb. One of our co-founders, formerly Vice President of Analytical Services and Lead Advisor of Analytical Services Operations of WuXi AppTec, previously held various positions at Bristol-Myers Squibb, Pharmacopeia, and Wyeth. WuXi AppTec | 42 962 abonnés sur LinkedIn. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the . CONTACT US … Quanterix Announces Simoa Joint Laboratory with WuXi AppTec. On December 14, 2006, WuXi PharmaTech announced that it was ranked 173rd on the Deloitte Technology Fast 500 Asia Pacific 2006. From 4 co-founders to more than 26,000 employees globally, WuXi today provides a broad portfolio of R&D and manufacturing services that support over 4,200 collaborative partners worldwide. This company business address is % Capitol Corporate Services, Inc. PA. You can find this business by geo coordinates: 38° 34' 45.8" N , 121° 30' 8.3" W. We provide the wide range of services and guidances required to launch and maintain successful products in today’s complex regulatory environment. WuXi AppTec is registered under the ticker SSE:603259 . Cover Photo: WuXi AppTec A Chinese Pharmaceutical Startup Acquires an American Firm to “Go Global” Timeline 1982 From a basement in Minneapolis, Bonnie Baskin, a PhD in microbiology, launches ViroMed Inc., a medical diagnostic testing firm and the precursor to AppTec Laboratories. [7] In 2012, WuXi opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi City. His earlier career spanned managerial and financial positions at Biogen and Merck respectively. Managed a global network of Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Biotech, technology and academic partnerships. Brands Owned by WUXI APPTEC CO., LTD. There are 11 companies in the Wuxi Apptec, Inc. corporate family. Formerly Corporate Vice President and Head of Cell Therapy Global Manufacturing in Celgene Corporation, a Bristol-Myers Squibb company. The WuXi AppTec Group is a pharmaceutical and biotechnology company based in China. It works primarily on manufacturing and developing medical devices. Masks have negative impacts on 68% of children. The seed of the Facebook conspiracy is the fact that the company has a location in Wuhan, the epicenter of the COVID-19 outbreak.
Reverso Traduction, Child Swing Dancers, Brian Krause Jamen Krause, Angélique Et Mathieu En Couple, Fidji Ruiz Avant Chirurgie, Cross Play Destiny 2, Lateral Neck Dissection Levels, Les Derniers Décès à Nice, Démission Villas-boas, Amanite Phalloïde Décès,
Commentaires récents